| [1] Pirmohamed, M. Personalized pharmacogenomics: predicting efficacy and adverse drug reactions. Annu. Rev. Genomics Hum. Genet. 2014, 15, 349-370.
[2] Shuldiner, R.; Relling, V.; Peterson, F.; Hicks, K.; Freimuth, R.; Sadee, W.; Pereira, L.; Roden, M.; Johnson, A.; Klein, E. The pharmacogenomics research network translational pharmacogenetics program: Overcoming challenges of real-world implementation. Clin. Pharmacol. Ther. 2013, 94, 207-210.
[3] Dunnenberger, H.M.; Crews, K.R.; Hoffman, J.M.; Caudle, K.E.; Broeckel, U.; Howard, S.C.; Hunkler, R.J.; Klein, T.E.; Evans, W.E.; Relling, M.V. Preemptive clinical pharmacogenetics implementation: Current programs in five US medical centers. Annu. Rev. Pharmacol. Toxicol. 2015, 55, 89-106.
[4] Anderson, J.L.; Horne, B.D.; Stevens, S.M.; Woller, S.C.; Samuelson, K.M.; Mansfield, J.W.; Robinson, M.; Barton, S.; Brunisholz, K.; Mower, C.P.; Huntinghouse, J.A.; Rollo, J.S.; Siler, D.; Bair, T.L.; Knight, S.; Muhlestein, J.B.; Carlquist, J.F. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation. 2012, 125, 1997-2005.
[5] Kamali, F.; Wynne, H. Pharmacogenetics of warfarin. Annu. Rev. Med. 2010, 61, 63-75.
[6] Nguyen, T.A.; Diodati, J.G.; Pharand, C. Resistance to clopidogrel: A review of the evidence. J. Am. Coll. Cardiol. 2005, 45, 1157-1164.
[7] Guo, Y.M.; Zhao, Z.C.; Zhang, L.; Li, H.Z.; Li, Z.; Sun, H.L. CYP2C19 polymorphisms in acute coronary syndrome patients undergoing clopidogrel therapy in Zhengzhou population. Genet. Mol. Res. 2016, 15. doi: 10.4238/gmr.15028012.
[8] Zhuo, Z.L.; Xian, H.P.; Long, Y.; Liu, C.; Sun, Y.Y.; Ma, Y.T.; Gao, H.; Zhao, J.Z.; Zhao, X.T. Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients. Anatol. J. Cardiol. 2018, 19, 123-129.
[9] Catena, C.; Colussi, G.; Url-Michitsch, M.; Nait, F.; Sechi, L.A. Subclinical carotid artery disease and plasma homocysteine levels in patients with hypertension. J. Am. Soc. Hypertens. 2015, 9, 167-175.
[10] Ford, A.H.; Flicker, L.; Singh, U.; Hirani, V.; Almeida, O.P. Homocysteine, depression and cognitive function in older adults. J. Affect. Disord. 2013, 151, 646-651.
[11] Huo, Y.; Li, J.P.; Qin, X.H.; Huang, Y.N.; Wang, X.B.; Gottesman, R.F.; Tang, G.F.; Wang, B.Y.; Chen, D.F.; He, M.L.; Fu, J.; Cai, Y.F.; Shi, X.L.; Zhang, Y.; Cui, Y.M.; Sun, N.L.; Li, X.Y.; Cheng, X.S.; Wang, J.N.; Yang, X.C.; Yang, T.L.; Xiao, C.S.; Zhao, G.; Dong, Q.; Zhu, D.L.; Wang, X.; Ge, J.B.; Zhao, L.Y.; Hu, D.Y.; Liu, L.S.; Hou, F.F. CSPPT Investigators, Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. JAMA. 2015, 313, 1325-1335.
[12] Klein, T.E.; Chang, J.T.; Cho, M.K.; Easton, K.L.; Fergerson, R.; Hewett, M.; Lin, Z.; Liu, Y.; Liu, S.; Oliver, D.E.; Rubin, D.L.; Shafa, F.; Stuart, J.M.; Altman, R.B. Integrating genotype and phenotype information: An overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base. Pharmacogenomics J. 2001, 1, 167-170.
[13] Thorn, C.F.; Klein, T.E.; Altman, R.B. Pharmacogenomics and bioinformatics: PharmGKB. Pharmacogenomics. 2010, 11, 501-505.
[14] Zhang, G.Q.; Zhang, Y.S.; Ling, Y.C.; Jia, J. Web resources for pharmacogenomics. Genomics Proteomics Bioinformatics. 2015, 13, 51-54. |
>
>